Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc acquired 468,356 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $12.48 per share, with a total value of $5,845,082.88. Following the acquisition, the director now owns 16,802,141 shares of the company’s stock, valued at $209,690,719.68. This trade represents a 2.87 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The shares were acquired at an average cost of $11.49 per share, for a total transaction of $3,684,728.10.
- On Friday, January 17th, Ecor1 Capital, Llc purchased 19,748 shares of Zymeworks stock. The stock was acquired at an average cost of $13.87 per share, with a total value of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc acquired 39,029 shares of Zymeworks stock. The shares were acquired at an average price of $14.01 per share, for a total transaction of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The stock was bought at an average price of $13.39 per share, with a total value of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc purchased 204,098 shares of Zymeworks stock. The shares were bought at an average price of $13.13 per share, for a total transaction of $2,679,806.74.
- On Wednesday, January 8th, Ecor1 Capital, Llc acquired 21,021 shares of Zymeworks stock. The shares were bought at an average price of $14.07 per share, with a total value of $295,765.47.
- On Thursday, January 2nd, Ecor1 Capital, Llc acquired 157,880 shares of Zymeworks stock. The shares were bought at an average price of $14.78 per share, with a total value of $2,333,466.40.
- On Monday, December 30th, Ecor1 Capital, Llc bought 58,988 shares of Zymeworks stock. The stock was bought at an average price of $14.47 per share, for a total transaction of $853,556.36.
- On Tuesday, December 24th, Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock. The shares were purchased at an average price of $14.12 per share, with a total value of $168,846.96.
- On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The stock was purchased at an average price of $14.38 per share, for a total transaction of $240,030.96.
Zymeworks Stock Performance
Shares of NYSE ZYME opened at $12.55 on Friday. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70. The firm has a market cap of $873.19 million, a P/E ratio of -8.37 and a beta of 1.13. The stock has a fifty day moving average price of $13.96 and a two-hundred day moving average price of $13.65.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on Zymeworks
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ZYME. Polar Asset Management Partners Inc. bought a new stake in Zymeworks in the fourth quarter worth about $527,000. Voloridge Investment Management LLC bought a new stake in shares of Zymeworks in the 4th quarter worth approximately $640,000. Point72 Asset Management L.P. raised its holdings in shares of Zymeworks by 565.8% in the 4th quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock worth $4,833,000 after purchasing an additional 280,544 shares in the last quarter. Nuveen Asset Management LLC lifted its stake in Zymeworks by 0.4% during the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock valued at $3,031,000 after purchasing an additional 886 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in Zymeworks by 1.2% during the fourth quarter. Deutsche Bank AG now owns 1,546,772 shares of the company’s stock worth $22,645,000 after buying an additional 17,849 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.
Zymeworks Company Profile
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Stories
- Five stocks we like better than Zymeworks
- How to Profit From Value Investing
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Financial Services Stocks Investing
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.